JNJ
JOHNSON & JOHNSONJOHNSON & JOHNSON reported revenue of $94.19B in its most recent fiscal year, up 6.0% on the year before. It kept 28.5% of that as net income, and generated $19.70B of free cash flow. Figures below are compared against other companies classified under Pharmaceutical Preparations.
Grades vs. industry
Growth
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Revenue growth (YoY) Latest fiscal year revenue vs. the year before. | 6.0% | 7.4% | 114 / 219 |
Revenue growth (3y) Annualized revenue growth over three fiscal years. | 5.6% | 7.6% | 97 / 186 |
Revenue growth (5y) Annualized revenue growth over five fiscal years. | 2.7% | 7.3% | 105 / 169 |
EPS growth (YoY) Diluted EPS vs. the prior fiscal year. | 90.5% | -33.3% | 10 / 49 |
EPS growth (3y) Annualized diluted EPS growth over three fiscal years. | 17.9% | 4.0% | 7 / 28 |
EPS growth (5y) Annualized diluted EPS growth over five fiscal years. | 14.9% | 3.8% | 7 / 29 |
Free cash flow growth (YoY) Operating cash flow less capital expenditure, vs. prior year. | -0.7% | -7.9% | 21 / 51 |
Free cash flow growth (3y) Annualized free cash flow growth over three fiscal years. | 4.7% | 1.4% | 13 / 33 |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Profitability
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Gross margin Gross profit as a share of revenue. Often unreported. | 67.9% | 72.1% | 65 / 116 |
Operating margin Operating income as a share of revenue. | Not reported | -34.2% | — |
Net margin Net income as a share of revenue. | 28.5% | -30.0% | 21 / 173 |
Free cash flow margin Free cash flow as a share of revenue. | 20.9% | -15.3% | 25 / 156 |
Return on equity Net income divided by shareholder equity. | 32.9% | -52.3% | 14 / 368 |
Return on assets Net income divided by total assets. | 13.5% | -37.6% | 22 / 419 |
Return on invested capital After-tax operating profit over debt plus equity less cash. | Not reported | -49.3% | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Financial health
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Debt to equity Total debt divided by shareholder equity. | 0.59x | 0.24x | 75 / 108 |
Current ratio Current assets over current liabilities. | 1.03x | 4.17x | 381 / 419 |
Quick ratio Current assets excluding inventory, over current liabilities. | 0.77x | 3.84x | 388 / 419 |
Interest coverage Operating income divided by interest expense. | Not reported | -15.21x | — |
Net debt to EBITDA Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed. | Not reported | -1.56x | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Debt figures can be understated where a filer splits borrowings across XBRL tags this site does not match.
Dividend coverage
Measures how much of earnings and free cash flow the dividend consumes, against industry peers. A low grade means the dividend is less covered than peers' — not that a cut is expected. Long-established payers often score low here by design.
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Dividend payout ratio Dividends paid as a share of net income. | Not reported | 45.5% | — |
Dividend / free cash flow Dividends paid as a share of free cash flow. The stricter test. | Not reported | 55.7% | — |
Dividend growth (5y) Annualized growth in dividends per share over five years. | 5.2% | 5.8% | 6 / 9 |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Dividend record
What the dividend has actually done, not a prediction of what it will do. Changes are checked against total dollars paid so that stock splits are not mistaken for cuts.
Dividend history is limited to what companies have filed in machine-readable form, which generally begins around 2009. A company may have paid or raised its dividend for far longer than shown here.
Insider activity
Trades reported by officers, directors and 10% shareholders on SEC Form 4. None of the last 22 reported transactions were open-market purchases — grants, option exercises and sales make up the majority of insider filings at most companies.
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 8, 2026 | HEWSON MARILLYN A Director | Grant or award(derivative) | 181 | $276.31 | $50.0K |
| Sep 8, 2026 | Woods Eugene A. Director | Grant or award(derivative) | 136 | $276.31 | $37.5K |
| Sep 8, 2026 | Pinto Daniel E Director | Grant or award(derivative) | 113 | $276.31 | $31.3K |
| Sep 2, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Open-market sale | 22,527 | $274.74 | $6.19M |
| Sep 2, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Option exercise | 22,527 | $151.41 | $3.41M |
| Sep 2, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Open-market sale | 11,070 | $274.74 | $3.04M |
| Sep 2, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Option exercise | 11,070 | $131.94 | $1.46M |
| Sep 2, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Option exercise(derivative) | 11,070 | $0.00 | $0.00 |
| Sep 2, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Option exercise(derivative) | 22,527 | $0.00 | $0.00 |
| Aug 17, 2026 | Taubert Jennifer L EVP, WWC. Innovative Medicine | Open-market sale | 15,000 | $263.36 | $3.95M |
| Aug 17, 2026 | Taubert Jennifer L EVP, WWC. Innovative Medicine | Option exercise | 15,000 | $115.67 | $1.74M |
| Aug 17, 2026 | Taubert Jennifer L EVP, WWC. Innovative Medicine | Option exercise(derivative) | 15,000 | $0.00 | $0.00 |
| Aug 13, 2026 | Duato Joaquin CEO and Chairman of the Board | Open-market sale | 102,315 | $261.00 | $26.70M |
| Aug 13, 2026 | Duato Joaquin CEO and Chairman of the Board | Option exercise | 123,291 | $115.67 | $14.26M |
| Aug 13, 2026 | Duato Joaquin CEO and Chairman of the Board | Open-market sale | 20,976 | $262.00 | $5.50M |
| Aug 13, 2026 | Duato Joaquin CEO and Chairman of the Board | Option exercise(derivative) | 123,291 | $0.00 | $0.00 |
| Aug 6, 2026 | Forminard Elizabeth EVP, Chief Legal Officer | Open-market sale | 9,344 | $257.75 | $2.41M |
| Aug 6, 2026 | Forminard Elizabeth EVP, Chief Legal Officer | Open-market sale | 6,574 | $255.93 | $1.68M |
| Aug 6, 2026 | Forminard Elizabeth EVP, Chief Legal Officer | Option exercise | 9,344 | $131.94 | $1.23M |
| Aug 6, 2026 | Forminard Elizabeth EVP, Chief Legal Officer | Option exercise(derivative) | 9,344 | $0.00 | $0.00 |
| Aug 5, 2026 | Duato Joaquin CEO and Chairman of the Board | Open-market sale | 41,957 | $258.06 | $10.83M |
| Aug 5, 2026 | Duato Joaquin CEO and Chairman of the Board | Open-market sale | 6,523 | $258.74 | $1.69M |
A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.
Annual financials
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B | $82.58B | $82.06B | $81.58B | $76.45B | $71.89B |
| Gross profit | $63.94B | $61.35B | $58.61B | $55.39B | $55.34B | $54.16B | $54.50B | $54.49B | $51.01B | $50.10B |
| Net income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B | $15.30B | $1.30B | $16.54B |
| EPS (diluted) | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 | $5.51 | $5.63 | $5.61 | $0.47 | $5.93 |
| Operating cash flow | $24.53B | $24.27B | $22.79B | $21.19B | $23.41B | $23.54B | $23.42B | $22.20B | $21.06B | $18.77B |
| Capital expenditure | $4.83B | $4.42B | $4.54B | $4.01B | $3.65B | $3.35B | $3.50B | $3.67B | $3.28B | $3.23B |
| Free cash flow | $19.70B | $19.84B | $18.25B | $17.18B | $19.76B | $20.19B | $19.92B | $18.53B | $17.78B | $15.54B |
| Total assets | $199.21B | $180.10B | $167.56B | $187.38B | $182.02B | $174.89B | $157.73B | $152.95B | $157.30B | $141.21B |
| Shareholder equity | $81.54B | $71.49B | $68.77B | $76.80B | $74.02B | $63.28B | $59.47B | $59.75B | $60.16B | $70.42B |
| Total debt | $47.94B | $36.65B | $29.38B | $39.69B | $33.78B | $35.23B | $27.69B | $30.48B | $34.58B | $27.14B |
| Cash | $19.71B | $24.11B | $21.86B | $12.89B | $14.49B | $13.98B | $17.30B | $18.11B | $17.82B | $18.97B |
| Dividends per share | $5.14 | $4.91 | $4.70 | $4.45 | $4.19 | $3.98 | $3.75 | $3.54 | $3.32 | $3.15 |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
Source
Figures come from JOHNSON & JOHNSON’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 10-K filed Feb 11, 2026. View filings on EDGAR.